Kathleen Wilson, PhD
Family · Tallahassee, FLNPI 1679728026
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $128,495 of the $153,813 with a category attached, or 83.5%. Novo Nordisk accounts for 93.9% of it on its own, with 37 other manufacturers making up the rest. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 365 payments — averaging $421.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$144K
- Sanofi-aventis U.S. LLC$2K
- Bayer$2K
- Esperion Therapeutics, Inc.$857
- Amgen$810
- Lilly USA, LLC$712
- plus $3K from 32 others
What the payments were for
- Consulting fees$8541%
- Speaking & faculty fees$128,49584%
- Travel & lodging$12,6588%
- Food & beverage$11,7418%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 220 | $144,442 |
| Sanofi-aventis U.S. LLC | 12 | $1,840 |
| Bayer | 16 | $1,661 |
| Esperion Therapeutics, Inc. | 2 | $857 |
| Amgen(2 entities) | 10 | $810 |
| Lilly USA, LLC | 13 | $712 |
| AstraZeneca(2 entities) | 13 | $596 |
| Medtronic | 8 | $447 |
| Abbott | 11 | $425 |
| Dexcom, Inc. | 9 | $326 |
| BETA Bionics, Inc. | 5 | $252 |
| AbbVie | 6 | $190 |
| Boston Scientific | 1 | $137 |
| Corcept Therapeutics | 2 | $123 |
| Eisai Inc. | 1 | $123 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $98 |
| Genentech, Inc. | 1 | $94 |
| Novartis | 4 | $89 |
| Astellas Pharma US Inc | 3 | $69 |
| Ascendis Pharma Endocrinology Inc | 2 | $45 |
| Kyowa Kirin, Inc. | 3 | $44 |
| Merck | 3 | $43 |
| Genentech USA, Inc. | 1 | $42 |
| Exact Sciences | 2 | $40 |
| Radius Health, Inc. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Boehringer Ingelheim | 1 | $29 |
| Tolmar, Inc. | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Mckesson Medical-surgical, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$153,813 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 622 | $711,927 |
| JardianceEmpagliflozin | 232 | $190,518 |
| FarxigaDapagliflozin Propanediol | 157 | $110,947 |
| TrulicityDulaglutide | 62 | $82,957 |
| RybelsusSemaglutide | 50 | $53,145 |
| MounjaroTirzepatide | 35 | $52,111 |
| JanuviaSitagliptin Phosphate | 63 | $48,864 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $48,325 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $36,482 |
| Humalog Kwikpen U-100Insulin Lispro | 114 | $36,083 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $32,049 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 32 | $30,543 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $29,550 |
| JanumetSitagliptin Phos/Metformin Hcl | 34 | $26,698 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 127 | $19,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Tresiba | $144,442 | $784,432719 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $29 | $218,810261 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro, Humulin 70-30 | $712 | $147,936176 claims |
| AstraZenecaFarxiga | $596 | $110,947157 claims |
| MerckJanuvia, Janumet, Janumet Xr | $43 | $86,853122 claims |
| AbbVieSynthroid | $190 | $4,18865 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $17 | $3,95712 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $2,559143 claims |
| Sanofi-aventis U.S. LLCLantus | $1,840 | $1,99419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Tallahassee
- Brittany YatesTallahassee$73K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.